Comparative Pharmacology
Head-to-head clinical analysis: CONEXXENCE versus ORTHO NOVUM 7 7 7 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONEXXENCE versus ORTHO NOVUM 7 7 7 21.
CONEXXENCE vs ORTHO-NOVUM 7/7/7-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CONEXXENCE is a combination hormonal contraceptive that suppresses gonadotropin (FSH and LH) release via inhibition of hypothalamic GnRH, thereby preventing ovulation. The progestin component (desogestrel) also increases cervical mucus viscosity and alters endometrial receptivity.
Combined hormonal contraceptive; primarily suppresses ovulation via inhibition of gonadotropin release (LH and FSH) from the pituitary. Also induces changes in cervical mucus and endometrium.
CONEXXENCE is not a recognized pharmaceutical agent. No standard dosing information available.
One tablet orally once daily for 21 days, followed by 7 days of no tablets. Each tablet contains norethindrone 0.5 mg/0.75 mg/1 mg and ethinyl estradiol 35 mcg, with biphasic or triphasic dosing per cycle.
None Documented
None Documented
Terminal elimination half-life: 12–18 hours; allows twice-daily dosing; prolonged in severe renal impairment (up to 40 hours).
Ethinyl estradiol: 13-27 hours; norethindrone: 8-14 hours; with multiple dosing, steady state after 5-7 days.
Renal: 70% unchanged; fecal: 30% (including metabolites).
Renal: <10% unchanged; biliary/fecal: ~50% as metabolites; extensive enterohepatic recirculation.
Category C
Category C
Oral Contraceptive
Oral Contraceptive